By Chris Wack


OncoSec Medical Inc. said it has entered into a collaboration and supply agreement with Merck & Co. to evaluate the combination of OncoSec's interleukin-12 Tavo with Merck's anti-cancer immunotherapy Keytruda in a global clinical trial.

OncoSec said the planned Phase 3 trial would evaluate the overall survival of patients treated with Tavo and Keytruda versus standard of care in late-stage patients with metastatic melanoma who are refractory to immune checkpoint therapy.

Tavo has received fast-track designation from the U.S. Food and Drug Administration as a potentially first-in-class, intratumoral anti-cancer gene therapy that expresses IL-12 for the treatment of metastatic melanoma, following progression on Keytruda or Opdivo.

The new trial is intended to support accelerated approval by the U.S. FDA and/or serve as a pivotal study to support a full licensure, OncoSec said.

Under the terms of the agreement, each party will be responsible for its own internal costs, with OncoSec covering third-party costs.

The study intends to enroll 400 patients and is planned to be conducted in the U.S., Canada, the European Union and Australia.

OncoSec shares were up 37% to $3.82 in premarket trading.


Write to Chris Wack at


(END) Dow Jones Newswires

July 07, 2021 06:37 ET (10:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Merck Charts.